Threshold is a biotechnology company focused on the discovery and development of therapeutics based on Tumor Hypoxia, a powerful scientific platform that offers broad potential to treat most solid tumors. By selectively targeting tumor cells, we are building a pipeline of drugs that hold promise to be more effective and less toxic to healthy tissues than conventional drugs.
TH-302 is a hypoxia-activated prodrug (HAP) for the potential treatment of solid tumors. TH-302, which was discovered at Threshold, is a novel drug candidate that is activated under the metabolic conditions typical of cancer cells. We started a Phase 1 clinical trial in July 2007 and, since then, have initiated four additional clinical trials of TH-302. The most advanced clinical is a Phase 2 multi-center, randomized, controlled, crossover clinical trial of TH-302 in combination with gemcitabine in patients with first line pancreatic cancer.
Glufosfamide has been investigated for the potential treatment of pancreatic cancer, small cell lung cancer, platinum-resistant ovarian cancer and advanced soft tissue sarcoma. The soft tissue sarcoma trial provided evidence of clinical activity. Additionally, in a phase 2 clinical trial of glufosfamide in combination with gemcitabine for the treatment of advanced pancreatic cancer, the data indicated that glufosfamide plus gemcitabine may benefit patients with chemotherapy naive pancreatic cancer. The Company will be seeking a partner to continue development of glufosfamide in cancer.
2-Deoxyglucose, or 2DG, for the treatment of solid tumors, has been evaluated in a Phase 1 clinical trial alone and in combination with Taxotere. The Company is no longer pursuing any clinical development with 2DG.
For more information visit www.thresholdpharm.com